Project Grant R21CA292276
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $429K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $816,554 to The University of Texas M.D. Anderson Cancer Center to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) associated with colorectal cancer and oxaliplatin treatment. The project aims to establish the face, construct, and predictive validity of this refined mouse...
- This Project Grant award, totaling $268,470.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The project will study the impacts of recent state-level laws legalizing medical cannabidiol (CBD) on substance use, including CBD use, opioid use, and alcohol use, as well as associated overdose rates. The research team, led by the RAND Corporation, will also collect and publish data on CBD dispensary locations and...
- The National Cancer Institute (NCI) awarded a $179,403 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the University of Nebraska Medical Center (UNMC) to develop and screen novel flupirtine analogue compounds as non-opioid analgesics for treating chemotherapy-induced neuropathic pain (CINP). The 2-year project aims to synthesize and evaluate flupirtine analogues that can effectively relieve CINP while mitigating the liver toxicity concerns associated with the parent...
- This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $181,448 to Virginia Commonwealth University (VCU) to research the use of the NLRP3 inflammasome inhibitor dapansutrile for treating chemotherapy-induced peripheral neuropathy (CIPN). The project aims to determine if dapansutrile can alleviate and prevent CIPN caused by paclitaxel and cisplatin chemotherapy in mouse models, including both naive and...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- The federal Project Grant award R21DA057513, funded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), will support research to determine the functional efficacy and selectivity of cannabidiol in ameliorating heroin-associated side effects in non-human primates. The $232,500 award will be used to investigate cannabidiol's ability to attenuate the abuse-related effects of heroin and modulate heroin-induced respiratory...
- This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
- The Project Grant award of $675,107 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The project, led by Northeastern University, will focus on designing and evaluating "dualsteric modulators" that act as both cannabinoid CB1 receptor...
- This $391,325 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of non-invasive, quantitative microscopic biomarkers to assess chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. The principal investigator, Dr. Kang from the University of Arizona, is leading the effort to utilize portable confocal microscopy (PCM) technology to visualize changes in Meissner's corpuscles, which are nerve...
- The National Cancer Institute (NCI) awarded a $404,295 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Media REZ LLC (doing business as Daniel Greenberg & Associates) on September 8, 2025. This multi-phase project aims to develop and assess a patient-centered, patient-driven virtual reality (VR) intervention to improve the management of chronic cancer pain. Specifically, the project will: 1) Identify patient perceptions around chronic cancer pain...